NEW YORK (GenomeWeb) – Gene editing firm Cellectis today priced its initial public offering of 5.5 million American Depositary Shares at $41.50 per ADS.
Each ADS represents one share of the Paris-based firm.
The company anticipates the ADSs to start trading on the Nasdaq Global Market today under ticker symbol "CLLS," and has granted the offering's underwriters a 30-day option to purchase up to an additional 825,000 shares. Bank of America Merrill Lynch, Jefferies, and Piper Jaffray are the joint book-running managers for the offering while Oppenheimer and Trout Capital are co-managers.
Cellectis was founded in 1999 with technology licensed from the Institut Pasteur and focuses on developing immunotherapies based on engineered chimeric antigen receptor (CAR)-T cells. It offers products based on TAL effector nuclease technology, meganucleases, and pulse agile technology, according to the company's website.
Cellectis operates three business divisions: bioresearch, cancer therapy, and plant sciences, which is based inMinnesota. In January the firm reached a deal with Ohio State University to develop and commercialize CAR technology targeting multiple myeloma cells.
Last December it and the Two Blades Foundation signed a cross-licensing deal for their respective TALEN technologies.